Structure Therapeutics Inc. Share Price Today, Financials & AI Analysis — Stockinder

Jarvis is thinking

Structure Therapeutics Inc. Share Price Today, Financials & AI Analysis — Stockinder

Income Statement

	2025-12-31	2024-12-31	2023-12-31
Profit from core operations after subtracting the cost of revenue and operating expenses like R&D and marketing, but before interest and taxes.	-$176.56M	-$158.23M	-$102.78M
The company's bottom-line profit after all expenses, interest, and taxes are subtracted.	-$141.20M	-$122.53M	-$89.62M
Net income divided by the number of shares outstanding — profit attributable to each share.	$-0.80	$-0.78	$-0.81
Like basic EPS, but accounts for shares that could be created from stock options or convertible securities — a more conservative per-share profit figure.	$-0.80	$-0.78	$-0.81

Balance Sheet

	2025-12-31	2024-12-31	2023-12-31
Cash and highly liquid short-term investments the company can access almost immediately.	$799.62M	$169.51M	$129.79M
Everything the company owns that has value — cash, property, inventory, investments, and more.	$1.58B	$903.33M	$482.02M
Everything the company owes — debt, unpaid bills, and other obligations.	$67.54M	$38.49M	$29.05M
What would be left for shareholders if the company sold all its assets and paid off all its debts — total assets minus total liabilities.	$1.52B	$864.84M	$452.97M

Cash Flow Statement

	2025-12-31	2024-12-31	2023-12-31
Actual cash generated by the core business, as opposed to accounting profit, which can include non-cash items.	-$222.20M	-$116.64M	-$79.49M
Cash spent on physical assets like property, equipment, and infrastructure to maintain or grow the business.	$3.61M	$1.29M	$2.17M
Cash left over after capital expenditures — money the company could use for dividends, buybacks, debt repayment, or reinvestment.	-$225.81M	-$117.93M	-$81.66M

Peer Comparison

	You	Peer avg
P/E	–	15.1
Revenue Growth	–	+26.9%
ROE	-20.2%	5.2%